10x Genomics (NASDAQ:TXG) Shares Down 8.7%
10x Genomics (NASDAQ:TXG) Shares Down 8.7%
10x Genomics, Inc. (NASDAQ:TXG – Get Rating) dropped 8.7% during trading on Tuesday . The company traded as low as $33.31 and last traded at $33.64. Approximately 9,354 shares traded hands during trading, a decline of 99% from the average daily volume of 990,602 shares. The stock had previously closed at $36.86.
10倍基因公司(納斯達克代碼：TXG-GET評級)在週二的交易中下跌了8.7%。該公司股價低至33.31美元，最新報33.64美元。約有9,354股股票在交易中成交，較990,602股的日均成交量下降了99%。該股此前收盤價為36.86美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
TXG has been the subject of a number of research analyst reports. The Goldman Sachs Group downgraded shares of 10x Genomics from a "neutral" rating to a "sell" rating and dropped their price objective for the company from $55.00 to $35.00 in a research note on Thursday, August 18th. Cowen boosted their target price on 10x Genomics to $55.00 in a report on Monday, August 15th. Morgan Stanley decreased their target price on 10x Genomics from $100.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday, August 10th. Canaccord Genuity Group assumed coverage on 10x Genomics in a report on Monday, July 25th. They set a "buy" rating and a $55.00 target price for the company. Finally, Cowen boosted their target price on 10x Genomics from $50.00 to $55.00 in a report on Tuesday, August 9th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $49.25.
TXG已經成為許多研究分析師報告的主題。在8月18日星期四的一份研究報告中，高盛將10x基因組公司的股票評級從中性下調至賣出，並將該公司的目標價從55美元下調至35美元。考恩在8月15日週一的一份報告中將其對10x基因組公司的目標價上調至55.00美元。摩根士丹利在8月10日(週三)的一份報告中將10x基因組學的目標價從100.00美元下調至70美元，並對該公司設定了“增持”評級。Canaccel Genuity Group在7月25日星期一的一份報告中承擔了10x基因組學的報道。他們為該公司設定了“買入”評級和55.00美元的目標價。最後，考恩在8月9日(星期二)的一份報告中將10x基因組公司的目標價從50.00美元上調至55.00美元。兩名股票研究分析師將該股評級為賣出，兩名分析師給予持有評級，五名分析師給予該股買入評級。根據MarketBeat的數據，該股目前的平均評級為持有，共識目標價為49.25美元。
10x Genomics Price Performance
10倍基因組學性價比
The stock has a fifty day simple moving average of $39.17 and a two-hundred day simple moving average of $50.45.
該股的50日簡單移動均線為39.17美元，200日簡單移動均線為50.45美元。
Insider Activity
內幕活動
In other news, CFO Justin J. Mcanear sold 987 shares of the stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total transaction of $34,732.53. Following the completion of the transaction, the chief financial officer now directly owns 58,092 shares in the company, valued at approximately $2,044,257.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Serge Saxonov sold 2,715 shares of the company's stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total transaction of $95,540.85. Following the sale, the chief executive officer now directly owns 966,102 shares of the company's stock, valued at approximately $33,997,129.38. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Justin J. Mcanear sold 987 shares of the company's stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $35.19, for a total value of $34,732.53. Following the sale, the chief financial officer now directly owns 58,092 shares in the company, valued at $2,044,257.48. The disclosure for this sale can be found here. In the last three months, insiders sold 4,994 shares of company stock worth $175,739. 11.08% of the stock is currently owned by insiders.
在其他新聞方面，首席財務官賈斯汀·J·曼坎爾在8月23日星期二的一筆交易中出售了987股該公司股票。該股以35.19美元的平均價格出售，總成交金額為34732.53美元。交易完成後，首席財務官現在直接擁有該公司58,092股，價值約2,044,257.48美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過這個鏈接訪問。在相關新聞中，首席執行官Serge Saxonov在8月23日星期二的一筆交易中出售了2,715股公司股票。該股以35.19美元的平均價格出售，總成交金額為95540.85美元。出售後，首席執行官現在直接擁有966,102股公司股票，價值約33,997,129.38美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，通過這個超級鏈接可以訪問微博。此外，首席財務官賈斯汀·J·曼坎爾在8月23日(星期二)的一次交易中出售了987股該公司股票。這些股票的平均價格為35.19美元，總價值為34,732.53美元。出售後，首席財務官現在直接持有該公司58,092股，價值2,044,257.48美元。此次拍賣的披露信息可在此處找到。在過去的三個月裏，內部人士出售了4994股公司股票，價值175,739美元。該公司11.08%的股份目前由內部人士持有。
Institutional Investors Weigh In On 10x Genomics
機構投資者參與10倍基因組學
Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of 10x Genomics by 14.2% during the 1st quarter. BlackRock Inc. now owns 9,156,992 shares of the company's stock valued at $696,572,000 after acquiring an additional 1,138,358 shares in the last quarter. Baillie Gifford & Co. increased its position in 10x Genomics by 13.9% in the second quarter. Baillie Gifford & Co. now owns 8,378,971 shares of the company's stock worth $379,148,000 after buying an additional 1,023,207 shares during the period. Vanguard Group Inc. increased its position in 10x Genomics by 2.4% in the first quarter. Vanguard Group Inc. now owns 7,732,523 shares of the company's stock worth $588,213,000 after buying an additional 178,481 shares during the period. FMR LLC increased its position in 10x Genomics by 50.2% in the second quarter. FMR LLC now owns 6,195,527 shares of the company's stock worth $280,347,000 after buying an additional 2,070,318 shares during the period. Finally, ARK Investment Management LLC increased its position in 10x Genomics by 6.2% in the second quarter. ARK Investment Management LLC now owns 3,603,286 shares of the company's stock worth $184,452,000 after buying an additional 211,948 shares during the period. 74.10% of the stock is owned by institutional investors and hedge funds.
幾家機構投資者和對衝基金最近對他們在該公司的頭寸進行了調整。貝萊德股份有限公司在第一季度將其持有的10x基因組公司股票的頭寸提高了14.2%。貝萊德股份有限公司在上個季度增持了1,138,358股後，目前持有該公司9,156,992股股票，價值696,572,000美元。Baillie Gifford&Co.在第二季度將其在10x基因組公司的頭寸增加了13.9%。Baillie Gifford&Co.在此期間又購買了1,023,207股，目前持有8,378,971股該公司股票，價值379,148,000美元。先鋒集團(Vanguard Group Inc.)第一季度將其在10x基因組公司的頭寸增加了2.4%。先鋒集團目前持有該公司7,732,523股股票，價值588,213,000美元，在此期間又購買了178,481股。FMR LLC在第二季度將其在10倍基因組公司的頭寸增加了50.2%。FMR LLC現在擁有6,195,527股該公司的股票，價值280,347,000美元，在此期間又購買了2,070,318股。最後，方舟投資管理有限責任公司在第二季度將其在10倍基因組公司的頭寸增加了6.2%。方舟投資管理公司目前持有該公司3,603,286股股票，價值184,452,000美元，在此期間又購買了211,948股。74.10%的股票由機構投資者和對衝基金持有。
10x Genomics Company Profile
10倍基因組學公司簡介
(Get Rating)
(獲取評級)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
10x基因組公司是一家生命科學技術公司，在北美、歐洲、中東、非洲、中國和亞太地區開發和銷售用於分析生物系統的儀器、消耗品和軟件。本公司提供鉻及鉻連接儀器、微流控芯片、載玻片、試劑等耗材產品。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on 10x Genomics (TXG)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- 免費獲取StockNews.com關於10x基因組學(TXG)的研究報告
- 這家醫療設備製造商準備好繼續反彈了嗎？
- 第三季度財報公佈前最值得關注的五(5)只股票
- Take-Two Interactive是否已經退化為一招小馬？
- 隨着收購傳言的甚囂塵上，Lyft能否成功？
- 健康飲料製造商Celsius能否超越其Monster競爭對手？
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得10倍基因組學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對10x基因組學和相關公司的最新新聞和分析師評級的每日簡明摘要。